Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sutro Biopharma, Inc. - Common Stock (NQ:STRO)

8.000 +7.270 (+995.89%)
Streaming Delayed Price Updated: 2:51 PM EST, Dec 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sutro Biopharma, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
58 Biggest Movers From Yesterday ↗
Gainers Eargo, Inc. (NASDAQ: EAR) shares climbed 59.7% to close at $7.28 on Thurs after the company announced the Department of Justice confirmed to it that the previously-... 
Via Benzinga
News headline image
Sutro Biopharma Collapses; Why One Analyst Remains Bullish On Its Chances In Cancer ↗
Sutro Biopharma could still find a place for itself in ovarian cancer treatment. 
Via Investor's Business Daily
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
Gainers Eargo (NASDAQ:EAR) stock increased by 50.0% to $6.84 during Thursday's regular session. The current volume of 90.4 million shares is 5474.6% of Eargo's... 
Via Benzinga
News headline image
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Thursday ↗
On Thursday, 615 stocks hit new 52-week lows. Noteable 52-Week Lows: Sea (NYSE:SE) is the largest company in terms of market cap to set a new 52-week low this... 
Via Benzinga
News headline image
33 Stocks Moving In Thursday's Mid-Day Session ↗
Gainers Eargo, Inc. (NASDAQ: EAR) shares jumped 50.8% to $6.88 after the company announced the Department of Justice confirmed to it that the previously-announced criminal probe... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Lilly Strikes Neurological R&D Collaboration, Valneva Confirms Vaccine Timelines, Biohaven Gains On Strong Migraine Drug Sales ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Illumina Announces Co-Development Partnership With SomaScan For Accelerating... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Pfizer-BioNTech Partner For Shingles Vaccine, Annexon Huntington Disease Study Disappoints, Amneal Buys Neurology Assets ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Annexon Announces Mixed Phase 2 Data From Huntington Disease Trial Annexon,... 
Via Benzinga
News headline image
The Week Ahead In Biotech (Jan. 2-Jan. 8): Stray Clinical Readouts In Focus In Slow News Week ↗
Biotech stocks came under selling pressure in the final week of 2021, although they carved out modest gains for the year. Here are the key catalysts that can sway biotech stocks in the unfolding week. 
Via Talk Markets
News headline image
The Week Ahead In Biotech (Jan 2-Jan. 8): Stray Clinical Readouts In Focus In Slow News Week ↗
Biotech stocks came under selling pressure in the final week of 2021, although they carved out modest gains for the year. On the regulatory front, the Food And Drug Administration... 
Via Benzinga
News headline image
Week In Review: Tasly Pharma Acquires Sutro ADC In $385 Million Deal ↗
Tasly Pharma acquired Greater China rights to an antibody-drug conjugate from Sutro Biopharma in a deal worth up to $385 million. Sutro will receive an upfront payment of $40 million and be eligible... 
Via Talk Markets
News headline image
Sutro Biopharma Earnings Perspective: Return On Capital Employed ↗
Benzinga Pro data, Sutro Biopharma (NASDAQ:STRO) reported Q3 sales of $8.52 million. Earnings fell to a loss of $34.67 million, resulting in a 253.64% decrease from last quarter... 
Via Benzinga
News headline image
Week In Review: Hansoh Signs $456 Million Deal For siRNA Products ↗
Hansoh Pharma of Shanghai announced a $456 million agreement to develop siRNA products in Greater China from South Korea's OliX Pharma. Hansoh will make an upfront payment of $6.5 million and up to... 
Via Talk Markets
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For November 17, 2021 ↗
Upgrades According to Williams Capital, the prior rating for On Holding AG (NYSE: 
Via Benzinga
News headline image
Merck, Sutro Biopharma Extends Cytokine Derivative Research Program ↗
Merck & Co Inc (NYSE: MRK) has extended the research term by two years for the first cytokine derivative program under a 2018 agreement with Sutro... 
Via Benzinga
News headline image
Sutro Biopharma Earnings Perspective: Return On Capital Employed ↗
According to Benzinga Pro data, during Q2, Sutro Biopharma (NASDAQ:STRO) posted sales of $28.05 million. Earnings were up 48.42%, but Sutro Biopharma still reported an overall... 
Via Benzinga
News headline image
Sutro Biopharma's Ovarian Cancer Candidate Fast Tracked In US ↗
The FDA has granted Fast Track designation to Sutro Biopharma Inc's (NASDAQ: STRO) STRO-002 for ovarian cancer. The designation covers platinum-resistant... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 18, 2021 ↗
Upgrades According to JP Morgan, the prior rating for Orion Engineered Carbons SA (NYSE: 
Via Benzinga
News headline image
Sutro Biopharma Receives Undisclosed Milestone Payment Under Bispecific ADC Collaboration with Merck ↗
Sutro Biopharma Inc (NASDAQ: STRO) has received a milestone payment under its collaboration and license agreement with the healthcare division of Merck KGaA... 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.